ライフサイエンスコーパス: standardized incidence ratio

1 out the standardized mortality ratio and the standardized incidence ratio.

2 red with that of the US population, based on standardized incidence ratio.

3 -years of follow-up; 36.5 had been expected (standardized incidence ratio = 0.85, 95% confidence inte

4 t increased in users of combination therapy (standardized incidence ratio = 0.93, 95% confidence inte

5 ed, as compared with 109.7 expected cancers (standardized incidence ratio, 0.98; 95% confidence inter

6 disease, a number similar to that expected (standardized incidence ratio = 1.2, 95% confidence inter

7 ciated with an increased risk of meningioma (standardized incidence ratio = 1.29, 95% confidence inte

8 optees without a biological parent with VTE (standardized incidence ratio) 1.51 (95% confidence inter

9 isk varied with sex and was greatest in men (standardized incidence ratio, 1.03 [95% CI, 1.02-1.03];

10 her than expected in the general population (standardized incidence ratio, 1.48; 95% confidence inter

11 E (n=156) were not at increased risk of VTE (standardized incidence ratio=1.07, 0.91-1.25).

12 levation was stronger than for systemic NHL (standardized incidence ratio=11.5; N = 2043).

13 with 4.4 expected in the general population (standardized incidence ratio, 18.1; 95 percent confidenc

14 much higher than in the general population (standardized incidence ratio, 19.1; 95% CI, 18.1 to 20.0

15 million person-years) and rhabdomyosarcoma (standardized incidence ratio, 2.62; 95% CI, 1.26 to 4.82

16 agnosed with VTE before the age of 50 years (standardized incidence ratio=2.03, 1.24-3.14).

17 o were treated with chest radiation therapy (standardized incidence ratio, 24.7 [95% CI, 19.3 to 31.0

18 sed for epilepsies without identified cause (standardized incidence ratio 3.8).

19 d incidence of malignancies other than NMSC (standardized incidence ratio, 3.04; 95% confidence inter

20 eased by 3-fold for NIA-LOAD/NCRAD families (standardized incidence ratio, 3.44) and 2-fold among the

21 ed with an increased risk of hepatoblastoma (standardized incidence ratio, 3.64; 95% CI, 1.34 to 7.93

22 or epilepsy of prenatal/developmental cause (standardized incidence ratio 4.1).

23 h we denoted 'prenatal/developmental cause' (standardized incidence ratio 4.3).

24 ted in recipients with versus without tBKVN (standardized incidence ratios 4.5 vs. 1.7; N = 48 cases)

25 ort was at a 4.5-fold increased risk of CHF (standardized incidence ratio = 4.5), compared with the g

26 dence interval [CI], 1.66-5.10) and of NMSC (standardized incidence ratio, 4.59; 95% CI, 2.51-7.70).

27 osis, 291 SMNs were ascertained in 261 CCSs (standardized incidence ratio, 5.2; 95% CI, 4.6 to 5.8; e

28 ands with idiopathic generalized epilepsies (standardized incidence ratio 6.0) and epilepsies associa

29 re not treated with chest radiation therapy (standardized incidence ratios, 6.7 and 7.6, respectively

30 PCNSL compared with the general population (standardized incidence ratio = 65.1; N = 168), and this

31 east cancer was the most common solid tumor (standardized incidence ratio 75.3; 95 percent confidence

32 opulation-based CRE incidence, site-specific standardized incidence ratios (adjusted for age and race

33 Compared with the general population, standardized incidence ratios among patients with an ind

34 The standardized incidence ratios and 95% confidence interva

35 ation immunosuppression were cancer-specific standardized incidence ratios and a multivariate hazard

36 in this cohort with population rates, using standardized incidence ratios and Cox proportional-hazar

37 Standardized incidence ratios and cumulative incidence f

38 We calculated standardized incidence ratios and cumulative incidence o

39 Annual incidences, standardized incidence ratios, and cumulative risks of b

40 As secondary analyses, the standardized incidence ratios (based on 2 cases for each

41 Standardized incidence ratios, based on age-specific can

42 Relative risks (RRs) were estimated using standardized incidence ratios, comparing the observed nu

43 Standardized incidence ratios declined for subsequent ma

44 Standardized incidence ratios did not differ by type or

45 ttransplant lymphoproliferative disease have standardized incidence ratios exceeding 10- or 50-fold.

46 We calculated standardized incidence ratios, excess absolute risks, an

47 The standardized incidence ratio for all malignancies (prima

48 The standardized incidence ratio for all malignant neoplasms

49 The standardized incidence ratio for any second cancer was 2

50 The standardized incidence ratio for HL with respect to age-

51 The standardized incidence ratio for patients with BD-IPMNs

52 s per 100,000 patient-years, and the overall standardized incidence ratio for suicide was 1.84 (95% c

53 The standardized incidence ratio for VTE was highest for ado

54 Standardized incidence ratios for all cancer were 84 in

55 Standardized incidence ratios for breast cancer were cal

56 The standardized incidence ratios for colorectal cancer were

57 The standardized incidence ratios for death due to neuroblas

58 imated age-specific cumulative incidence and standardized incidence ratios for epilepsy in relatives

59 Standardized incidence ratios for post-transplant cardia

60 Cumulative incidence of SNs and standardized incidence ratios for second malignant neopl

61 We calculated standardized incidence ratios for siblings versus the ge

62 cumulative incidence, cumulative burden, and standardized incidence ratios for subsequent malignancie

63 Standardized incidence ratios for suicide among patient

64 The relative risk (standardized incidence ratio) for venous thromboembolism

65 Familial standardized incidence ratio (FSIR), relative risks (RRs

66 us squamous cell carcinoma, have the highest standardized incidence ratios in transplant recipients.

67 n women and 73 in men, with a large range of standardized incidence ratios observed for specific canc

68 A lung cancer standardized incidence ratio of 0.44 (95% confidence int

69 first cancer was 107.8 x 10,000 PY, giving a standardized incidence ratio of 1.1 (95% CI: 0.83-1.41).

70 A prostate cancer standardized incidence ratio of 1.14 (95% confidence int

71 among the exposed daughters, resulting in a standardized incidence ratio of 40.7 (95% CI, 13.1-126.2

72 The 3- to <12-month standardized incidence ratio of cancer was 1.5 (95% CI,

73 reased compared with the general population (standardized incidence ratio of VTE, 4.2; 95% CI, 3.9 to

74 We calculated risks and standardized incidence ratios of cancer for patients wit

75 The standardized incidence ratios of CRC were 2.2 for all IB

76 causes of death and cumulative incidence and standardized incidence ratios of key medical morbidities

77 cond cancer in HL survivors and compared the standardized incidence ratios of lung, breast, colorecta

78 Standardized incidence ratios showed excess risk for all

79 ated compared with California women overall (standardized incidence ratio (SIR) = 0.9, 95% confidence

80 or overall cancer incidence in male workers (standardized incidence ratio (SIR) = 0.91, 95% confidenc

81 elevated risks of all cancers combined (PCT: standardized incidence ratio (SIR) = 1.7, 95% confidence

82 The standardized incidence ratio (SIR) for all cancers was 1

83 this study was to determine the rate of and standardized incidence ratio (SIR) for lymphoma in patie

84 re diagnosed in 908 patients, resulting in a standardized incidence ratio (SIR) of 4.6 (95% confidenc

85 ma in situ developed in 373 patients, with a standardized incidence ratio (SIR) of 5.0 (95% CI, 4.5 t

86 The calculated standardized incidence ratio (SIR) showed that mutation

87 The standardized incidence ratio (SIR) was calculated as the

88 Standardized incidence ratio (SIR) was used to estimate

89 All studies were included that reported a standardized incidence ratio (SIR), standardized mortali

90 The standardized incidence ratio (SIR), with 95% confidence

91 We obtained standardized incidence ratios (SIR) and excess absolute

92 Standardized incidence ratios (SIR) were calculated to c

93 o the general population were assessed using standardized incidence ratios (SIR).

94 ncreased relative to the general population (standardized incidence ratio [SIR] 1.80, 95%CI 1.51-2.12

95 ed significantly for acute myeloid leukemia (standardized incidence ratio [SIR] 52.3), non-Hodgkin ly

96 ndrome (MDS) or acute myeloid leukemia (AML; standardized incidence ratio [SIR] = 300; 95% CI, 210 to

97 A four-fold increased breast cancer risk (standardized incidence ratio [SIR] = 4.0; 95% CI, 3.0 to

98 ancy compared with an expected number of 79 (standardized incidence ratio [SIR], 1.1; 95% CI, 0.9 to

99 he risk for ESRD in the cohort was elevated (standardized incidence ratio [SIR], 1.37; 95% confidence

100 4.3 expected from general population rates (standardized incidence ratio [SIR], 11.6, 95% confidence

101 ng SNs compared with the general population (standardized incidence ratio [SIR], 18.5, 95% CI, 15.6 t

102 ral Swedish and Danish populations combined (standardized incidence ratio [SIR], 2.0; 95% CI, 1.6-2.4

103 higher than that in the general population (standardized incidence ratio [SIR], 2.81 [95% CI, 2.10 t

104 was significantly elevated for liver cancer (standardized incidence ratio [SIR], 27.7; 95% confidence

105 h HL was 0.6%, which represents a threefold (standardized incidence ratio [SIR], 3.3; 95% confidence

106 ung field) had a high risk of breast cancer (standardized incidence ratio [SIR], 43.6; 95% CI, 27.2 t

107 ed after CLL/SLL and FL but not after DLBCL (standardized incidence ratio [SIR], CLL/SLL = 1.42, FL =

108 and higher incidences of de novo malignancy (standardized incidence ratio [SIR]=3.94, 95% CI, 2.09-6.

109 Standardized incidence ratios (SIRs) adjusted for age, r

110 Standardized incidence ratios (SIRs) and excess absolute

111 Standardized incidence ratios (SIRs) and standardized mo

112 Standardized incidence ratios (SIRs) and standardized mo

113 Standardized incidence ratios (SIRs) and standardized mo

114 the background population were expressed as standardized incidence ratios (SIRs) and standardized mo

115 The standardized incidence ratios (SIRs) and the 5- and 10-y

116 Risk of skin cancer was analyzed using standardized incidence ratios (SIRs) and, for SCC, multi

117 Standardized incidence ratios (SIRs) compared HL risk in

118 Standardized incidence ratios (SIRs) compared incidence

119 Standardized incidence ratios (SIRs) expressing risk of

120 Standardized incidence ratios (SIRs) for all SMNs combin

121 Standardized incidence ratios (SIRs) for cancer were cal

122 We calculated age- and sex-adjusted standardized incidence ratios (SIRs) for CRC in both gro

123 relatives, and calculated the registry-based standardized incidence ratios (SIRs) for different cance

124 Standardized incidence ratios (SIRs) for senile cataract

125 Standardized incidence ratios (SIRs) for solid tumors we

126 Standardized incidence ratios (SIRs) measured the effect

127 The standardized incidence ratios (SIRs) of autism and ADHD

128 e estimated country-, age-, and sex-specific standardized incidence ratios (SIRs) of cancer for carri

129 cs of patients and the age- and sex-adjusted standardized incidence ratios (SIRs) of cancer in famili

130 The standardized incidence ratios (SIRs) of diffuse large B-

131 son regression models were used to calculate standardized incidence ratios (SIRs) of S aureus bactere

132 to identify HCC risk factors and calculated standardized incidence ratios (SIRs) to compare HCC risk

133 We used standardized incidence ratios (SIRs) to compare incidenc

134 Standardized incidence ratios (SIRs) were calculated as

135 Standardized incidence ratios (SIRs) were calculated by

136 Standardized incidence ratios (SIRs) were calculated by

137 Sex-specific age- and calendar-period standardized incidence ratios (SIRs) were calculated for

138 Standardized incidence ratios (SIRs) were calculated for

139 Standardized incidence ratios (SIRs) were calculated for

140 Standardized incidence ratios (SIRs) were calculated for

141 Standardized incidence ratios (SIRs) were calculated for

142 Standardized incidence ratios (SIRs) were calculated for

143 Standardized incidence ratios (SIRs) were calculated for

144 Standardized incidence ratios (SIRs) were calculated to

145 Standardized incidence ratios (SIRs) were calculated to

146 Standardized incidence ratios (SIRs) were calculated to

147 Standardized incidence ratios (SIRs) were calculated usi

148 Standardized incidence ratios (SIRs) were calculated usi

149 Standardized mortality ratios (SMRs) and standardized incidence ratios (SIRs) were calculated usi

150 Sex-specific standardized incidence ratios (SIRs) were calculated.

151 Standardized incidence ratios (SIRs) were computed as es

152 Age-, sex-, and race-adjusted standardized incidence ratios (SIRs) were computed, and

153 Age- and sex-standardized incidence ratios (SIRs) were estimated by r

154 Standardized incidence ratios (SIRs) were used for compa

155 Standardized incidence ratios (SIRs) were used to assess

156 Standardized incidence ratios (SIRs) with 95% confidence

157 We estimated sex-specific standardized incidence ratios (SIRs) with corresponding

158 Standardized incidence ratios (SIRs), a proxy measure fo

159 Standardized incidence ratios (SIRs), absolute excess ri

160 Risk was calculated using standardized incidence ratios (SIRs), and risk factors w

161 SPM risk was quantified by using standardized incidence ratios (SIRs), excess absolute ri

162 Cumulative incidence of SNs, standardized incidence ratios (SIRs), excess absolute ri

163 Sex and HIV risk group-specific standardized incidence ratios (SIRs), post-AIDS relative

164 We calculated standardized incidence ratios (SIRs), relative risks (RR

165 Childhood Cancer Survivor Study to calculate standardized incidence ratios (SIRs), using Surveillance

166 al population incidence rates by calculating standardized incidence ratios (SIRs).

167 ) with those of the general population using standardized incidence ratios (SIRs).

168 ents not exposed to biologics and calculated standardized incidence ratios (SIRs).

169 diagnoses and calculated absolute risks and standardized incidence ratios (SIRs).

170 mpared with risks in the general population (standardized incidence ratios [SIRs]) and the non-IVF gr

171 The standardized incidence ratio (the ratio of observed to e

172 We calculated standardized incidence ratios to compare anal cancer inc

173 The standardized incidence ratio was 1.5 (95 percent confide

174 The overall cancer standardized incidence ratio was 1.5 (95% confidence int

175 ogy, and End-Results) lymphoma database, the standardized incidence ratio was 1.8 (95% CI 1.5-2.2).

176 Standardized incidence ratio was 10.9 (95% CI, 6.6 to 17

177 patients with pericarditis was 2.7%, and the standardized incidence ratio was 12.4 (95% CI, 11.2-13.7

178 The adjusted standardized incidence ratio was 224.1 (95% confidence i

179 The overall standardized incidence ratio was 3.1 (95 percent confide

180 The standardized incidence ratio was 3.5 (95% confidence int

181 A prostate cancer standardized incidence ratio was computed for the cohort

182 The CRE standardized incidence ratio was significantly higher th

183 estimated by computing an age, sex, and race standardized incidence ratio, was 2.24 (95% confidence i

184 unpaired t tests, and age- and sex-adjusted standardized incidence ratio were calculated.

185 Breast cancer standardized incidence ratios were 0.87 (95% confidence

186 n relatives of probands with focal epilepsy, standardized incidence ratios were 1.0 (95% confidence i

187 because of a history of adenomatous polyps; standardized incidence ratios were 1.6 (CI, 1.2 to 2.2)

188 The standardized incidence ratios were 1.74 (0.94 to 2.37) f

189 s with </=17, 18-21, and >/=22 risk alleles, standardized incidence ratios were 1.76, 2.08, and 2.25,

190 tives of probands with generalized epilepsy, standardized incidence ratios were 8.3 (95% confidence i

191 Standardized incidence ratios were calculated by compari

192 Standardized incidence ratios were calculated for spousa